Verve Therapeutics, Inc. (VERV) Dividend History

Company News

• Verve Therapeutics to Participate in Upcoming Investor Conferences

  Verve Therapeutics reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating dose-dependent decreases in blood LDL-C and PCSK9 with a mean reduction in LDL-C of 53%.

  GlobeNewswire Inc.
• Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - Trump Tariffs Drive Pharma Manufacturing to US but Risk Inflation and Disruption

  The report examines the impact of Trump tariffs on pharmaceutical manufacturing, with a shift towards US-based production but potential risks of inflation and supply chain disruption.

  GlobeNewswire Inc.

  Featured Companies: LLY MRK PFE
• Why Verve Therapeutics Zoomed 40% Higher This Week

  Verve Therapeutics' stock price jumped 40% this week after the company published positive initial data from a phase 1b clinical trial of its drug VERVE-102, which targets a genetic disorder that causes high cholesterol levels. Several analysts raised their price targets for the stock, with one even upgrading it to a buy recommendation.

  The Motley Fool

  Featured Companies: JPM
• Why Verve Therapeutics Is Skyrocketing Today

  Verve Therapeutics stock is surging after the company reported positive results from a Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia. Several analysts have raised their price targets on the stock, citing the strong safety and efficacy data.

  The Motley Fool
• Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

  Verve Therapeutics announced that the FDA has granted Fast Track designation for VERVE-102, its investigational base editing medicine designed to lower LDL-C levels. The company is currently testing VERVE-102 in a Phase 1b clinical trial.

  GlobeNewswire Inc.

  Featured Companies: LLY